Patent intelligence · EP
EP 2651400
ORALE RETARD-DARREICHUNGSFORMEN VON SCHWER LÖSLICHEN ARZNEIMITTELN UND IHRE VERWENDUNG
ORALE RETARD-DARREICHUNGSFORMEN VON SCHWER LÖSLICHEN ARZNEIMITTELN UND IHRE VERWENDUNG
Patent details — EP 2651400
- Jurisdiction
- EP
- Status
- granted
- Grant date
- Oct 23, 2013
- Expiration
- Oct 18, 2033
- Applicant
- CELGENE CORP [US]
- CPC classes
- A61K 9/ 22 A I, A61K 9/ 24 A I, A61K 31/ 4035 A I, A61K/314035
Quick answer
EP 2651400 (ORALE RETARD-DARREICHUNGSFORMEN VON SCHWER LÖSLICHEN ARZNEIMITTELN UND IHRE VERWENDUNG) is held by CELGENE CORP [US]. Status: granted. Granted Oct 23, 2013. Expires Oct 18, 2033 (7 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- CELGENE CORP [US]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K 9/ 22 A I, A61K 9/ 24 A I, A61K 31/ 4035 A I, A61K/314035, A61K/4734, A61K/4736
More from CELGENE CORP [US]
Related pharmaceutical patents in our USPTO index.
-
EP 3539539
TABLETTENFORMULIERUNGEN AUS (+)-2-[1-(3-ETHOXY-4-METHOXYPHENYL)-2-METHYLSULFONYLETHYL]-4-ACETYLAMINOISOINDOLIN-1,3-DION
granted -
EP 3320902
VERFAHREN ZUR BEHANDLUNG VON ERKRANKUNGEN MIT ISOINDOLINVERBINDUNGEN
granted -
MX 2015008685
TREATMENT OF PSORIATIC ARTHRITIS USING APREMILAST.
granted -
AU 2012362562
Formulations of (+)-2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-4-acetyl aminoisoindoline-1,3-dione
granted -
AU 2012308663
Formulations of cyclopropanecarboxylic acid {2-[1S)-1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-3-oxo-2,3-dihydro-1H-isoindol-4-yl}-amidecelgene corporation state of incorporation:delaware
granted -
AU 2012249536
Methods and compositions using PDE4 inhibitors for the treatment and management of autoimmune and inflammatory diseases
granted -
AU 2013203283
Processes for the preparation of (S)-1-(3-ethoxy-4-methoxyophenyl)-2-methanesulfonylethylamine
granted
Frequently asked questions
What is US patent 2651400?
EP 2651400 (ORALE RETARD-DARREICHUNGSFORMEN VON SCHWER LÖSLICHEN ARZNEIMITTELN UND IHRE VERWENDUNG) is held by CELGENE CORP [US]. Status: granted. Granted Oct 23, 2013. Expires Oct 18, 2033 (7 years remaining) — relevant for patent-cliff and LOE planning.
Who owns EP 2651400?
CELGENE CORP [US] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 13 pharmaceutical patents for this assignee.
When does EP 2651400 expire?
Our index shows an expiration date of Oct 18, 2033 (7 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.